CGEN-25009 is a novel peptide of the LGR7 receptor that was discovered by Compugen’s GPCR Peptide Ligand Discovery Platform (Shemesh et al., 2008). The LGR7 receptor is known to be activated by Relaxin and therefore CGEN-25009 could potentially have therapeutic activity in various clinical indications including fibrosis, labor complications, infertility and heart failure. The anti-fibrotic and anti-inflammatory effects of CGEN-25009 were demonstrated in-vivo in a mouse model of bleomycin-induced pulmonary fibrosis, in which preventive and therapeutic modes of treatment by CGEN-25009 were found beneficial in reducing the density of the fibrotic tissue and various markers of inflammatory injury, induced by bleomycin (Pini et al., 2010). Therefore, CGEN-25009 could have a potential therapeutic utility to treat pulmonary fibrosis and other fibrosis related conditions such as chronic renal failure.

CGEN-25009 further development is being funded by the Pulmonary Fibrosis Foundation, and studies are undertaken at the University of Pittsburgh School of Medicine and the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease.